Nonviral approaches for neuronal delivery of nucleic acids

Pharmaceutical Research

Volumn 25, Issue 5, 2008, Pages 983-998

  Bergen, Jamie M ^a   Park, In Kyu ^a   Horner, Philip J ^a,b   Pun, Suzie H ^a  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CNS; Neuron targeting; Nonviral gene delivery; Nucleic acid delivery

Indexed keywords

ADENOVIRUS VECTOR; ATAXIN 1; BETA SECRETASE; BRAIN DERIVED NEUROTROPHIC FACTOR; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DNA; DYNEIN ADENOSINE TRIPHOSPHATASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HERPESVIRUS VECTOR; HUNTINGTIN; IMMUNOLIPOSOME; LENTIVIRUS VECTOR; LIPID; MEMBRANE METALLOENDOPEPTIDASE; NAKED DNA; NANOPARTICLE; NEUROPEPTIDE; NEUROTOXIN; NEUROTROPHIN; NUCLEIC ACID; PARVOVIRUS VECTOR; POLYMER; POLYPEPTIDE; SHORT HAIRPIN RNA; SOMATOMEDIN C; SUPEROXIDE DISMUTASE; TYROSINE 3 MONOOXYGENASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DNA TRANSFECTION; GENE EXPRESSION REGULATION; GENE TARGETING; HERPES SIMPLEX VIRUS; HUMAN; HUNTINGTON CHOREA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; RETROGRADE NERVE FIBER TRANSPORT; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; EXCIPIENTS; GENE THERAPY; HUMANS; NEURONS; NUCLEIC ACIDS; TRANSFECTION;

EID: 42049114012     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9439-5     Document Type: Review

References (142)

1. W. J. Bowers, D. F. Howard, and H. J. Federoff. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease. Exp. Neurol. 144:58-68 (1997).
2. B. Blits, and M. B. Bunge. Direct gene therapy for repair of the spinal cord. J. Neurotrauma. 23:508-520 (2006).
3. J. M. Alisky, and B. L. Davidson. Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases. Hum. Gene. Ther. 11:2315-2329 (2000).
4. R. Tinsley, and P. Eriksson. Use of gene therapy in central nervous system repair. Acta. Neurol. Scand. 109:1-8 (2004).
5. T. Federici, and N. M. Boulis. Gene-based treatment of motor neuron diseases. Muscle Nerve. 33:302-323 (2006).
6. B. K. Kaspar, J. Llado, N. Sherkat, J. D. Rothstein, and F. H. Gage. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 301:839-842 (2003).
7. A. P. Kells, D. M. Fong, M. Dragunow, M. J. During, D. Young, and B. Connor. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol. Ther. 9:682-688 (2004).
8. R. J. Mandel, S. K. Spratt, R. O. Snyder, and S. E. Leff. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. U S A. 94:14083-14088 (1997).
9. D. L. Choi-Lundberg, Q. Lin, T. Schallert, D. Crippens, B. L. Davidson, Y. N. Chang, Y. L. Chiang, J. Qian, L. Bardwaj, and M. C. Bohn. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. 154:261-275 (1998).
10. J. A. Gonzalez-Barrios, M. Lindahl, M. J. Bannon, V. Anaya-Martinez, G. Flores, I. Navarro-Quiroga, L. E. Trudeau, J. Aceves, D. B. Martinez-Arguelles, R. Garcia-Villegas, I. Jimenez, J. Segovia, and D. Martinez-Fong. Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol. Ther. 14:857-865 (2006).
11. Y. Zhang, F. Schlachetzki, Y. F. Zhang, R. J. Boado, and W. M. Pardridge. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum. Gene. Ther. 15:339-350 (2004).
12. M. J. During, J. R. Naegele, K. L. O'Malley, and A. I. Geller. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science. 266:1399-1403 (1994).
13. C. S. Hong, W. F. Goins, J. R. Goss, E. A. Burton, and J. C. Glorioso. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene. Ther. 13:1068-1079 (2006).
14. B. L. Davidson, and H. L. Paulson. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet. Neurol. 3:145-149 (2004).
15. E. Rodriguez-Lebron, and P. Gonzalez-Alegre. Silencing neurodegenerative disease: bringing RNA interference to the clinic. Expert. Rev. Neurother. 6:223-233 (2006).
16. A. Forte, M. Cipollaro, A. Cascino, and U. Galderisi. Small interfering RNAs and antisense oligonucleotides for treatment of neurological diseases. Curr. Drug. Targets. 6:21-29 (2005).
17. H. Xia, Q. Mao, S. L. Eliason, S. Q. Harper, I. H. Martins, H. T. Orr, H. L. Paulson, L. Yang, R. M. Kotin, and B. L. Davidson. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10:816-820 (2004).
18. S. Q. Harper, P. D. Staber, X. He, S. L. Eliason, I. H. Martins, Q. Mao, L. Yang, R. M. Kotin, H. L. Paulson, and B. L. Davidson. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U S A. 102:5820-5825 (2005).
19. G. S. Ralph, P. A. Radcliffe, D. M. Day, J. M. Carthy, M. A. Leroux, D. C. Lee, L. F. Wong, L. G. Bilsland, L. Greensmith, S. M. Kingsman, K. A. Mitrophanous, N. D. Mazarakis, and M. Azzouz. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11:429-433 (2005).
20. O. Singer, R. A. Marr, E. Rockenstein, L. Crews, N. G. Coufal, F. H. Gage, I. M. Verma, and E. Masliah. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8:1343-1349 (2005).
21. R. A. Dewey, G. Morrissey, C. M. Cowsill, D. Stone, F. Bolognani, N. J. Dodd, T. D. Southgate, D. Klatzmann, H. Lassmann, M. G. Castro, and P. R. Lowenstein. Chr]onic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat. Med. 5:1256-1263 (1999).
22. C. S. Peden, C. Burger, N. Muzyczka, and R. J. Mandel. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J. Virol. 78:6344-6359 (2004).
23. D. W. Pack, A. S. Hoffman, S. Pun, and P. S. Stayton. Design and development of polymers for gene delivery. Nat. Rev. Drug. Discov. 4:581-593 (2005).
24. O. Boussif, F. Lezoualc'h, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix, and J. P. Behr. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U S A. 92:7297-7301 (1995).
25. N. D. Sonawane, F. C. Szoka, Jr., and A. S. Verkman. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. 278:44826-44831 (2003).
26. B. Abdallah, A. Hassan, C. Benoist, D. Goula, J. P. Behr, and B. A. Demeneix. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum. Gene. Ther. 7:1947-1954 (1996).
27. M. Berry, L. Barrett, L. Seymour, A. Baird, and A. Logan. Gene therapy for central nervous system repair. Curr. Opin. Mol. Ther. 3:338-349 (2001).
28. G. P. Tang, J. M. Zeng, S. J. Gao, Y. X. Ma, L. Shi, Y. Li, H. P. Too, and S. Wang. Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. Biomaterials. 24:2351-2362 (2003).
29. L. Shi, G. P. Tang, S. J. Gao, Y. X. Ma, B. H. Liu, Y. Li, J. M. Zeng, Y. K. Ng, K. W. Leong, and S. Wang. Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord. Gene. Ther. 10:1179-1188 (2003).
30. L. Wasungu, and D. Hoekstra. Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release. 116:255-264 (2006).
31. S. Kaech, J. B. Kim, M. Cariola, and E. Ralston. Improved lipid-mediated gene transfer into primary cultures of hippocampal neurons. Brain. Res. Mol. Brain. Res. 35:344-348 (1996).
32. B. Wiesenhofer, and C. Humpel. Lipid-mediated gene transfer into primary neurons using FuGene: comparison to C6 glioma cells and primary glia. Exp. Neurol. 164:38-44 (2000).
33. M. T. da Cruz, S. Simoes, and M. C. de Lima. Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons. Exp. Neurol. 187:65-75 (2004).
34. E. C. Ohki, M. L. Tilkins, V. C. Ciccarone, and P. J. Price. Improving the transfection efficiency of post-mitotic neurons. J. Neurosci. Methods. 112:95-99 (2001).
35. S. Li, W. C. Tseng, D. B. Stolz, S. P. Wu, S. C. Watkins, and L. Huang. Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection. Gene. Ther. 6:585-594 (1999).
36. W. M. Pardridge. Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug. Discov. 1:131-139 (2002).
37. N. Shi, and W. M. Pardridge. Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. U S A. 97:7567-7572 (2000).
38. Y. Zhang, C. Zhu, and W. M. Pardridge. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6:67-72 (2002).
39. Y. Zhang, F. Calon, C. Zhu, R. J. Boado, and W. M. Pardridge. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene. Ther. 14:1-12 (2003).
40. S. Barati, F. Chegini, P. Hurtado, and R. A. Rush. Hybrid tetanus toxin C fragment-diphtheria toxin translocation domain allows specific gene transfer into PC12 cells. Exp. Neurol. 177:75-87 (2002).
41. N. Ma, S. S. Wu, Y. X. Ma, X. Wang, J. Zeng, G. Tong, Y. Huang, and S. Wang. Nerve growth factor receptor-mediated gene transfer. Mol. Ther. 9:270-281 (2004).
42. J. Zeng, H. P. Too, Y. Ma, E. S. Luo, and S. Wang. A synthetic peptide containing loop 4 of nerve growth factor for targeted gene delivery. J. Gene. Med. 6:1247-1256 (2004).
43. J. Zeng, and S. Wang. Enhanced gene delivery to PC12 cells by a cationic polypeptide. Biomaterials. 26:679-686 (2005).
44. Y. M. Usachev, A. Khammanivong, C. Campbell, and S. A. Thayer. Particle-mediated gene transfer to rat neurons in primary culture. Pflugers. Arch. 439:730-738 (2000).
45. J. J. Xiang, J. Q. Tang, S. G. Zhu, X. M. Nie, H. B. Lu, S. R. Shen, X. L. Li, K. Tang, M. Zhou, and G. Y. Li. IONP-PLL: a novel non-viral vector for efficient gene delivery. J. Gene. Med. 5:803-817 (2003).
46. D. J. Bharali, I. Klejbor, E. K. Stachowiak, P. Dutta, I. Roy, N. Kaur, E. J. Bergey, P. N. Prasad, and M. K. Stachowiak. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc. Natl. Acad. Sci. U S A. 102:11539-11544 (2005).
47. A. Gartner, L. Collin, and G. Lalli. Nucleofection of primary neurons. Methods Enzymol. 406:374-388 (2006).
48. P. G. Leclere, A. Panjwani, R. Docherty, M. Berry, J. Pizzey, and D. A. Tonge. Effective gene delivery to adult neurons by a modified form of electroporation. J. Neurosci. Methods. 142:137-143 (2005).
49. R. Morris, B. S. Morgan, T. M. Lewis, K. D. Pierce, A. Pisano, and P. R. Schofield. In vivo somatic delivery of plasmid DNA and retrograde transport to obtain cell-specific gene expression in the central nervous system. J. Neurochem. 90:1445-1452 (2004).
50. Y. Li, J. Wang, C. G. Lee, C. Y. Wang, S. J. Gao, G. P. Tang, Y. X. Ma, H. Yu, H. Q. Mao, K. W. Leong, and S. Wang. CNS gene transfer mediated by a novel controlled release system based on DNA complexes of degradable polycation PPE-EA: a comparison with polyethylenimine/DNA complexes. Gene Ther. 11:109-114 (2004).
51. B. H. Choi, Y. Ha, C. H. Ahn, X. Huang, J. M. Kim, S. R. Park, H. Park, H. C. Park, S. W. Kim, and M. Lee. A hypoxia-inducible gene expression system using erythropoietin 3′ untranslated region for the gene therapy of rat spinal cord injury. Neurosci. Lett. 412:118-122 (2007).
52. S. Barati, P. R. Hurtado, S. H. Zhang, R. Tinsley, I. A. Ferguson, and R. A. Rush. GDNF gene delivery via the p75(NTR) receptor rescues injured motor neurons. Exp. Neurol. 202:179-188 (2006).
53. X. Wang, C. Wang, J. Zeng, X. Xu, P. Y. Hwang, W. C. Yee, Y. K. Ng, and S. Wang. Gene transfer to dorsal root ganglia by intrathecal injection: effects on regeneration of peripheral nerves. Mol. Ther. 12:314-320 (2005).
54. M. T. da Cruz, A. L. Cardoso, L. P. de Almeida, S. Simoes, and M. C. de Lima. Tf-lipoplex-mediated NGF gene transfer to the CNS: neuronal protection and recovery in an excitotoxic model of brain injury. Gene. Ther. 12:1242-1252 (2005).
55. S. Wang, N. Ma, S. J. Gao, H. Yu, and K. W. Leong. Transgene expression in the brain stem effected by intramuscular injection of polyethylenimine/DNA complexes. Mol. Ther. 3:658-664 (2001).
56. F. Finiels, M. Gimenez y Ribotta, M. Barkats, M. L. Samolyk, J. J. Robert, A. Privat, F. Revah, and J. Mallet. Specific and efficient gene transfer strategy offers new potentialities for the treatment of motor neurone diseases. Neuroreport. 7:373-378 (1995).
57. J. Yamamura, S. Kageyama, T. Uwano, M. Kurokawa, M. Imakita, and K. Shiraki. Long-term gene expression in the anterior horn motor neurons after intramuscular inoculation of a live herpes simplex virus vector. Gene. Ther. 7:934-941 (2000).
58. G. F. Lemkine, D. Goula, N. Becker, L. Paleari, G. Levi, and B. A. Demeneix. Optimisation of polyethylenimine-based gene delivery to mouse brain. J. Drug. Target. 7:305-312 (1999).
59. P. Washbourne, and A. K. McAllister. Techniques for gene transfer into neurons. Curr. Opin. Neurobiol. 12:566-573 (2002).
60. E. H. Lo, A. B. Singhal, V. P. Torchilin, and N. J. Abbott. Drug delivery to damaged brain. Brain. Res. Brain. Res. Rev. 38:140-148 (2001).
61. D. Martinez-Fong, I. Navarro-Quiroga, I. Ochoa, I. Alvarez-Maya, M. A. Meraz, J. Luna, and J. A. Arias-Montano. Neurotensin-SPDP-poly-l-lysine conjugate: a nonviral vector for targeted gene delivery to neural cells. Brain. Res. Mol. Brain. Res. 69:249-262 (1999).
62. I. Navarro-Quiroga, J. Antonio Gonzalez-Barrios, F. Barron-Moreno, V. Gonzalez-Bernal, D. B. Martinez-Arguelles, and D. Martinez-Fong. Improved neurotensin-vector-mediated gene transfer by the coupling of hemagglutinin HA2 fusogenic peptide and Vp1 SV40 nuclear localization signal. Brain. Res. Mol. Brain. Res. 105:86-97 (2002).
63. J. Zeng, X. Wang, and S. Wang. Self-assembled ternary complexes of plasmid DNA, low molecular weight polyethylenimine and targeting peptide for nonviral gene delivery into neurons. Biomaterials. 28:1443-1451 (2007).
64. A. Knight, J. Carvajal, H. Schneider, C. Coutelle, S. Chamberlain, and N. Fairweather. Non-viral neuronal gene delivery mediated by the HC fragment of tetanus toxin. Eur. J. Biochem. 259:762-769 (1999).
65. J. K. Liu, Q. Teng, M. Garrity-Moses, T. Federici, D. Tanase, M. J. Imperiale, and N. M. Boulis. A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting. Neurobiol. Dis. 19:407-418 (2005).
66. I. K. Park, J. Lasiene, S. Chou, P. J. Horner, and S. H. Pun. Neuron-specific delivery of nucleic acids mediated by Tet1-modified poly(ethylenimine). J. Gene Med. 9:691-702 (2007).
67. K. A. Mislick, and J. D. Baldeschwieler. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc. Natl. Acad. Sci. U S A. 93:12349-12354 (1996).
68. C. G. Dotti, R. G. Parton, and K. Simons. Polarized sorting of glypiated proteins in hippocampal neurons. Nature. 349:158-161 (1991).
69. P. L. Cameron, T. C. Sudhof, R. Jahn, and P. De Camilli. Colocalization of synaptophysin with transferrin receptors: implications for synaptic vesicle biogenesis. J. Cell. Biol. 115:151-164 (1991).
70. J. S. Suk, J. Suh, K. Choy, S. K. Lai, J. Fu, and J. Hanes. Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles. Biomaterials. 27:5143-5150 (2006).
71. R. K. Margolis, S. R. Salton, and R. U. Margolis. Effects of nerve growth factor-induced differentiation on the heparan sulfate of PC12 pheochromocytoma cells and comparison with developing brain. Arch. Biochem. Biophys. 257:107-114 (1987).
72. J. M. Bergen and S. H. Pun. Analysis of the intracellular barriers encountered by nonviral gene carriers in a model of spatially-controlled delivery to neurons. J. Gene Medicine (2007) in press.
73. J. S. Suk, J. Suh, S. K. Lai, and J. Hanes. Quantifying the intracellular transport of viral and nonviral gene vectors in primary neurons. Exp. Biol. Med. (Maywood) 232:461-469 (2007).
74. E. Wagner. Application of membrane-active peptides for nonviral gene delivery. Adv. Drug Deliv. Rev. 38:279-289 (1999).
75. I. S. Zuhorn, U. Bakowsky, E. Polushkin, W. H. Visser, M. C. Stuart, J. B. Engberts, and D. Hoekstra. Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection efficiency. Mol. Ther. 11:801-810 (2005).
76. J. Suh, D. Wirtz, and J. Hanes. Efficient active transport of gene nanocarriers to the cell nucleus. Proc. Natl. Acad. Sci. U S A. 100:3878-3882 (2003).
77. S. Papadopoulos, K. D. Jurgens, and G. Gros. Protein diffusion in living skeletal muscle fibers: dependence on protein size, fiber type, and contraction. Biophys. J. 79:2084-2094 (2000).
78. S. M. King. The dynein microtubule motor. Biochim. Biophys. Acta. 1496:60-75 (2000).
79. R. B. Vallee, J. C. Williams, D. Varma, and L. E. Barnhart. Dynein: An ancient motor protein involved in multiple modes of transport. J. Neurobiol. 58:189-200 (2004).
80. M. Lakadamyali, M. J. Rust, H. P. Babcock, and X. Zhuang. Visualizing infection of individual influenza viruses. Proc. Natl. Acad. Sci. U S A. 100:9280-9285 (2003).
81. D. McDonald, M. A. Vodicka, G. Lucero, T. M. Svitkina, G. G. Borisy, M. Emerman, and T. J. Hope. Visualization of the intracellular behavior of HIV in living cells. J. Cell. Biol. 159:441-452 (2002).
82. P. L. Leopold, G. Kreitzer, N. Miyazawa, S. Rempel, K. K. Pfister, E. Rodriguez-Boulan, and R. G. Crystal. Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum. Gene Ther. 11:151-165 (2000).
83. K. Dohner, A. Wolfstein, U. Prank, C. Echeverri, D. Dujardin, R. Vallee, and B. Sodeik. Function of dynein and dynactin in herpes simplex virus capsid transport. Mol. Biol. Cell. 13:2795-2809 (2002).
84. G. A. Smith, and L. W. Enquist. Break ins and break outs: viral interactions with the cytoskeleton of Mammalian cells. Annu. Rev. Cell Dev. Biol. 18:135-161 (2002).
85. H. Mabit, M. Y. Nakano, U. Prank, B. Saam, K. Dohner, B. Sodeik, and U. F. Greber. Intact microtubules support adenovirus and herpes simplex virus infections. J. Virol. 76:9962-9971 (2002).
86. E. Mastrobattista, M. A. van der Aa, W. E. Hennink, and D. J. Crommelin. Artificial viruses: a nanotechnological approach to gene delivery. Nat. Rev. Drug Discov. 5:115-121 (2006).
87. R. N. Cohen, M. J. Rashkin, X. Wen, and F. C. Szoka. Molecular motors as drug delivery vehicles. Drug Discovery Today: Technologies. 2:111-118 (2005).
88. J. M. Bergen, and S. H. Pun. Evaluation of an LC8-binding peptide for the attachment of artificial cargo to dynein. Mol. Pharm. 4:119-128 (2007).
89. M. A. van der Aa, E. Mastrobattista, R. S. Oosting, W. E. Hennink, G. A. Koning, and D. J. Crommelin. The nuclear pore complex: the gateway to successful nonviral gene delivery. Pharm. Res. 23:447-459 (2006).
90. Y. L. Chiu, A. Ali, C. Y. Chu, H. Cao, and T. M. Rana. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 11:1165-1175 (2004).
91. R. Levi-Montalcini, and P. U. Angeletti. Nerve growth factor. Physiol. Rev. 48:534-569 (1968).
92. B. Georgievska, D. Kirik, and A. Bjorklund. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 177:461-474 (2002).
93. C. Rosenblad, B. Georgievska, and D. Kirik. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur. J. Neurosci. 17:260-270 (2003).
94. E. V. van Gaal, W. E. Hennink, D. J. Crommelin, and E. Mastrobattista. Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy. Pharm. Res. 23:1053-1074 (2006).
95. J. A. Benitez, and J. Segovia. Gene therapy targeting in the central nervous system. Curr. Gene. Ther. 3:127-145 (2003).
96. M. C. de Lima, M. T. da Cruz, A. L. Cardoso, S. Simoes, and L. P. de Almeida. Liposomal and viral vectors for gene therapy of the central nervous system. Curr. Drug Targets CNS Neurol. Disord. 4:453-465 (2005).
97. S. A. Betchen, and M. Kaplitt. Future and current surgical therapies in Parkinson's disease. Curr. Opin. Neurol. 16:487-493 (2003).
98. S. B. Dunnett, and A. E. Rosser. Cell therapy in Huntington's disease. NeuroRx. 1:394-405 (2004).
99. D. J. Begley. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104:29-45 (2004).
100. T. A. Read, F. Thorsen, and R. Bjerkvig. Localised delivery of therapeutic agents to CNS malignancies: old and new approaches. Curr. Pharm. Biotechnol. 3:257-273 (2002).
101. M. J. During, M. G. Kaplitt, M. B. Stern, and D. Eidelberg. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum. Gene Ther. 12:1589-1591 (2001).
102. B. Schwartz, C. Benoist, B. Abdallah, R. Rangara, A. Hassan, D. Scherman, and B. A. Demeneix. Gene transfer by naked DNA into adult mouse brain. Gene Ther. 3:405-411 (1996).
103. H. Sato, S. Hattori, S. Kawamoto, I. Kudoh, A. Hayashi, I. Yamamoto, M. Yoshinari, M. Minami, and H. Kanno. In vivo gene gun-mediated DNA delivery into rodent brain tissue. Biochem. Biophys. Res. Commun. 270:163-170 (2000).
104. H. Peluffo, L. Acarin, A. Aris, P. Gonzalez, A. Villaverde, B. Castellano, and B. Gonzalez. Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector. BMC Neurosci. 7:35 (2006).
105. Y. Hagihara, Y. Saitoh, Y. Kaneda, E. Kohmura, and T. Yoshimine. Widespread gene transfection into the central nervous system of primates. Gene Ther. 7:759-763 (2000).
106. J. Siepmann, F. Siepmann, and A. T. Florence. Local controlled drug delivery to the brain: mathematical modeling of the underlying mass transport mechanisms. Int. J. Pharm. 314:101-119 (2006).
107. S. Kalyanasundaram, V. D. Calhoun, and K. W. Leong. A finite element model for predicting the distribution of drugs delivered intracranially to the brain. Am. J. Physiol. 273:R1810-1821 (1997).
108. R. H. Bobo, D. W. Laske, A. Akbasak, P. F. Morrison, R. L. Dedrick, and E. H. Oldfield. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U S A. 91:2076-2080 (1994).
109. P. Hadaczek, Y. Yamashita, H. Mirek, L. Tamas, M. C. Bohn, C. Noble, J. W. Park, and K. Bankiewicz. The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol. Ther. 14:69-78 (2006).
110. M. T. Krauze, R. Saito, C. Noble, J. Bringas, J. Forsayeth, T. R. McKnight, J. Park, and K. S. Bankiewicz. Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp. Neurol. 196:104-111 (2005).
111. J. A. MacKay, D. F. Deen, and F. C. Szoka, Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res. 1035:139-153 (2005).
112. M. Y. Chen, R. R. Lonser, P. F. Morrison, L. S. Governale, and E. H. Oldfield. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J. Neurosurg. 90:315-320 (1999).
113. C. Mamot, J. B. Nguyen, M. Pourdehnad, P. Hadaczek, R. Saito, J. R. Bringas, D. C. Drummond, K. Hong, D. B. Kirpotin, T. McKnight, M. S. Berger, J. W. Park, and K. S. Bankiewicz. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J. Neurooncol. 68:1-9 (2004).
114. M. Y. Chen, A. Hoffer, P. F. Morrison, J. F. Hamilton, J. Hughes, K. S. Schlageter, J. Lee, B. R. Kelly, and E. H. Oldfield. Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J. Neurosurg. 103:311-319 (2005).
115. K. B. Neeves, C. T. Lo, C. P. Foley, W. M. Saltzman, and W. L. Olbricht. Fabrication and characterization of microfluidic probes for convection enhanced drug delivery. J. Control Release. 111:252-262 (2006).
116. G. H. Huynh, T. Ozawa, D. F. Deen, T. Tihan, and F. C. Szoka, Jr. Retro-convection enhanced delivery to increase blood to brain transfer of macromolecules. Brain Res. (2006).
117. D. D. Heistad and F. M. Faraci. Gene therapy for cerebral vascular disease. Stroke. 27:1688-1693 (1996).
118. J. G. Hecker, L. L. Hall, and V. R. Irion. Nonviral gene delivery to the lateral ventricles in rat brain: initial evidence for widespread distribution and expression in the central nervous system. Mol. Ther. 3:375-384 (2001).
119. D. M. Anderson, L. L. Hall, A. R. Ayyalapu, V. R. Irion, M. H. Nantz, and J. G. Hecker. Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: methods and evidence for nonviral mRNA gene delivery to the central nervous system. Hum. Gene Ther. 14:191-202 (2003).
120. L. F. Kromer. Nerve growth factor treatment after brain injury prevents neuronal death. Science. 235:214-216 (1987).
121. L. L. Zou, L. Huang, R. L. Hayes, C. Black, Y. H. Qiu, J. R. Perez-Polo, W. Le, G. L. Clifton, and K. Yang. Liposome-mediated NGF gene transfection following neuronal injury: potential therapeutic applications. Gene Ther. 6:994-1005 (1999).
122. D. K. Cope, and W. R. Lariviere. Gene therapy and chronic pain. ScientificWorld J. 6:1066-1074 (2006).
123. G. P. Tang, H. Y. Guo, F. Alexis, X. Wang, S. Zeng, T. M. Lim, J. Ding, Y. Y. Yang, and S. Wang. Low molecular weight polyethylenimines linked by beta-cyclodextrin for gene transfer into the nervous system. J. Gene Med. 8:736-744 (2006).
124. M. Box, D. A. Parks, A. Knight, C. Hale, P. S. Fishman, and N. F. Fairweather. A multi-domain protein system based on the HC fragment of tetanus toxin for targeting DNA to neuronal cells. J. Drug Target. 11:333-343 (2003).
125. H. Schneider, M. Groves, C. Muhle, P. N. Reynolds, A. Knight, M. Themis, J. Carvajal, F. Scaravilli, D. T. Curiel, N. F. Fairweather, and C. Coutelle. Retargeting of adenoviral vectors to neurons using the Hc fragment of tetanus toxin. Gene Ther. 7:1584-1592 (2000).
126. H. B. Rind, R. Butowt, and C. S. von Bartheld. Synaptic targeting of retrogradely transported trophic factors in motoneurons: comparison of glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor, and cardiotrophin-1 with tetanus toxin. J. Neurosci. 25:539-549 (2005).
127. R. S. Devon, P. C. Orban, K. Gerrow, M. A. Barbieri, C. Schwab, L. P. Cao, J. R. Helm, N. Bissada, R. Cruz-Aguado, T. L. Davidson, J. Witmer, M. Metzler, C. K. Lam, W. Tetzlaff, E. M. Simpson, J. M. McCaffery, A. E. El-Husseini, B. R. Leavitt, and M. R. Hayden. Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proc. Natl. Acad. Sci. U S A. 103:9595-9600 (2006).
128. C. M. Wiethoff, and C. R. Middaugh. Barriers to nonviral gene delivery. J. Pharm. Sci. 92:203-217 (2003).
129. I. K. Park, T. H. Kim, S. I. Kim, T. Akaike, and C. S. Cho. Chemical modification of chitosan for gene delivery. J. Dispers. Sci. Technol. 24:489-498 (2003).
130. R. J. Boado. RNA interference and nonviral targeted gene therapy of experimental brain cancer. NeuroRx. 2:139-150 (2005).
131. W. M. Pardridge. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx. 2:129-138 (2005).
132. W. M. Pardridge. Blood-brain barrier delivery. Drug Discov. Today. 12:54-61 (2007).
133. S. E. Doran, X. D. Ren, A. L. Betz, M. A. Pagel, E. A. Neuwelt, B. J. Roessler, and B. L. Davidson. Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption. Neurosurgery. 36:965-970 (1995).
134. N. G. Rainov, K. Ikeda, N. Qureshi, S. Grover, F. H. Barnett, U. Herrlinger, A. Quinones, E. A. Chiocca, and X. O. Breakefield. Intra-arterial virus and nonvirus vector-mediated gene transfer to experimental rat brain tumors. Front. Radiat. Ther. Oncol. 33:227-240 (1999).
135. N. G. Rainov, K. Ikeda, N. H. Qureshi, S. Grover, U. Herrlinger, P. Pechan, E. A. Chiocca, X. O. Breakefield, and F. H. Barnett. Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum. Gene Ther. 10:311-318 (1999).
136. A. Nadal, E. Fuentes, J. Pastor, and P. A. McNaughton. Plasma albumin is a potent trigger of calcium signals and DNA synthesis in astrocytes. Proc. Natl. Acad. Sci. U S A. 92:1426-1430 (1995).
137. A. S. Lossinsky, A. W. Vorbrodt, and H. M. Wisniewski. Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier. J. Neurocytol. 24:795-806 (1995).
138. T. S. Salahuddin, B. B. Johansson, H. Kalimo, and Y. Olsson. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. Acta Neuropathol. (Berl) 77:5-13 (1988).
139. J. Huwyler, D. Wu, and W. M. Pardridge. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U S A. 93:14164-14169 (1996).
140. F. Schlachetzki, Y. Zhang, R. J. Boado, and W. M. Pardridge. Gene therapy of the brain: the trans-vascular approach. Neurology. 62:1275-1281 (2004).
141. N. Shi, Y. Zhang, C. Zhu, R. J. Boado, and W. M. Pardridge. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U S A. 98:12754-12759 (2001).
142. Y. Zhang, F. Schlachetzki, and W. M. Pardridge. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther. 7:11-18 (2003).